New Paradigm in Combination Therapy of SiRNA with Chemotherapeutic Drugs for Effective Cancer Therapy

Overview

Journal Curr Res Pharmacol Drug Discov

Date 2022 May 19

PMID 35586474

Authors

Krishan Kumar

Varsha Rani

Mohini Mishra

Ruchi Chawla

Affiliations

Soon will be listed here.

Abstract

Chemotherapeutics drugs play a pivotal role in the treatment of cancer. However, many issues generate by chemotherapy drugs, including unfavorable harm to healthy cells and multidrug resistance (MDR), persist and have a negative impact on therapeutic outcomes. When compared to monotherapy, combination cancer therapy has many advantages, like improving efficacy through synergistic effects and overcoming drug resistance. Combination treatment may comprise several chemotherapeutics drugs and combinations of chemotherapeutic drugs with some other therapeutic options such as surgery or radiation. Cancer treatment that utilizes co-delivery strategies with siRNA and chemotherapeutic drugs has been shown to have highly effective antitumor effects in the treatment of many cancers. However, the highly complex mechanisms of chemotherapeutic drugs-siRNA pairs during the co-delivery process have received little attention. The ideal combination of chemotherapeutic drugs with siRNA is very crucial for producing the desirable anticancer effects that would greatly enhance therapeutic efficiency. This review puts an emphasis on the logic for choosing suitable chemotherapeutic drug-siRNA combinations, which may open the way for the co-delivery of chemotherapeutic drugs and siRNA for treating cancer in the clinic. This review summarizes recent breakthrough in the area of diverse mechanism-based chemotherapeutic drugs-siRNA combinations in cancer treatment.

Citing Articles

Advances and prospects of RNA delivery nanoplatforms for cancer therapy.

Attia M, Kijanka G, Nguyen N, Zhang J, An H Acta Pharm Sin B. 2025; 15(1):52-96.

PMID: 40041887 PMC: 11873661. DOI: 10.1016/j.apsb.2024.09.009.

Diagnostic and Therapeutic Advances of RNAs in Precision Medicine of Gastrointestinal Tumors.

Liu R, Zhou J, Chen X, Zhang J, Chen Q, Liu X Biomedicines. 2025; 13(1).

PMID: 39857631 PMC: 11762367. DOI: 10.3390/biomedicines13010047.

RNA nanotherapeutics for hepatocellular carcinoma treatment.

Yuan Y, Sun W, Xie J, Zhang Z, Luo J, Han X Theranostics. 2025; 15(3):965-992.

PMID: 39776807 PMC: 11700867. DOI: 10.7150/thno.102964.

Co-delivery of antioxidants and siRNA-VEGF: promising treatment for age-related macular degeneration.

Dias M, Cruz-Cazarim E, Pittella F, Baiao A, Pacheco A, Sarmento B Drug Deliv Transl Res. 2025; .

PMID: 39751765 DOI: 10.1007/s13346-024-01772-x.

Recent Advances and Prospects in RNA Drug Development.

Tani H Int J Mol Sci. 2024; 25(22).

PMID: 39596348 PMC: 11594839. DOI: 10.3390/ijms252212284.

References

Patil Y, Swaminathan S, Sadhukha T, Ma L, Panyam J . The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance. Biomaterials. 2009; 31(2):358-65. PMC: 2783414. DOI: 10.1016/j.biomaterials.2009.09.048. View

Yang Z, Li J, Wang Z, Dong D, Qi X . Tumor-targeting dual peptides-modified cationic liposomes for delivery of siRNA and docetaxel to gliomas. Biomaterials. 2014; 35(19):5226-39. DOI: 10.1016/j.biomaterials.2014.03.017. View

Itani R, Al Faraj A . siRNA Conjugated Nanoparticles-A Next Generation Strategy to Treat Lung Cancer. Int J Mol Sci. 2019; 20(23). PMC: 6929195. DOI: 10.3390/ijms20236088. View

Wu L, Leng D, Cun D, Foged C, Yang M . Advances in combination therapy of lung cancer: Rationales, delivery technologies and dosage regimens. J Control Release. 2017; 260:78-91. DOI: 10.1016/j.jconrel.2017.05.023. View

Li J, Wang Y, Zhu Y, Oupicky D . Recent advances in delivery of drug-nucleic acid combinations for cancer treatment. J Control Release. 2013; 172(2):589-600. PMC: 3783568. DOI: 10.1016/j.jconrel.2013.04.010. View

Crnkovic-Mertens I, Hoppe-Seyler F, Butz K . Induction of apoptosis in tumor cells by siRNA-mediated silencing of the livin/ML-IAP/KIAP gene. Oncogene. 2003; 22(51):8330-6. DOI: 10.1038/sj.onc.1206973. View

Gao Y, Liu X, Li X . Research progress on siRNA delivery with nonviral carriers. Int J Nanomedicine. 2011; 6:1017-25. PMC: 3124387. DOI: 10.2147/IJN.S17040. View

Foroozandeh P, Abdul Aziz A . Insight into Cellular Uptake and Intracellular Trafficking of Nanoparticles. Nanoscale Res Lett. 2018; 13(1):339. PMC: 6202307. DOI: 10.1186/s11671-018-2728-6. View

Sanita G, Carrese B, Lamberti A . Nanoparticle Surface Functionalization: How to Improve Biocompatibility and Cellular Internalization. Front Mol Biosci. 2020; 7:587012. PMC: 7726445. DOI: 10.3389/fmolb.2020.587012. View

10.

Mitchell E . Targeted therapy for metastatic colorectal cancer: role of aflibercept. Clin Colorectal Cancer. 2012; 12(2):73-85. DOI: 10.1016/j.clcc.2012.08.001. View

11.

Lam J, Liang W, Chan H . Pulmonary delivery of therapeutic siRNA. Adv Drug Deliv Rev. 2011; 64(1):1-15. PMC: 7103329. DOI: 10.1016/j.addr.2011.02.006. View

12.

Weiss M, Fan J, Claudel M, Sonntag T, Didier P, Ronzani C . Density of surface charge is a more predictive factor of the toxicity of cationic carbon nanoparticles than zeta potential. J Nanobiotechnology. 2021; 19(1):5. PMC: 7789233. DOI: 10.1186/s12951-020-00747-7. View

13.

Ewert K, Zidovska A, Ahmad A, Bouxsein N, Evans H, McAllister C . Cationic liposome-nucleic acid complexes for gene delivery and silencing: pathways and mechanisms for plasmid DNA and siRNA. Top Curr Chem. 2011; 296:191-226. PMC: 3867951. DOI: 10.1007/128_2010_70. View

14.

Yin T, Wang P, Li J, Wang Y, Zheng B, Zheng R . Tumor-penetrating codelivery of siRNA and paclitaxel with ultrasound-responsive nanobubbles hetero-assembled from polymeric micelles and liposomes. Biomaterials. 2014; 35(22):5932-43. DOI: 10.1016/j.biomaterials.2014.03.072. View

15.

Phyo P, Zhao X, Templeton A, Xu W, Cheung J, Su Y . Understanding molecular mechanisms of biologics drug delivery and stability from NMR spectroscopy. Adv Drug Deliv Rev. 2021; 174:1-29. DOI: 10.1016/j.addr.2021.02.007. View

16.

Hillaireau H, Couvreur P . Nanocarriers' entry into the cell: relevance to drug delivery. Cell Mol Life Sci. 2009; 66(17):2873-96. PMC: 11115599. DOI: 10.1007/s00018-009-0053-z. View

17.

Zhang B, Lung P, Zhao S, Chu Z, Chrzanowski W, Li Q . Shape dependent cytotoxicity of PLGA-PEG nanoparticles on human cells. Sci Rep. 2017; 7(1):7315. PMC: 5544670. DOI: 10.1038/s41598-017-07588-9. View

18.

Zhao Z, Li Y, Liu H, Jain A, Patel P, Cheng K . Co-delivery of IKBKE siRNA and cabazitaxel by hybrid nanocomplex inhibits invasiveness and growth of triple-negative breast cancer. Sci Adv. 2020; 6(29):eabb0616. PMC: 7439402. DOI: 10.1126/sciadv.abb0616. View

19.

Beh C, Seow W, Wang Y, Zhang Y, Ong Z, Ee P . Efficient delivery of Bcl-2-targeted siRNA using cationic polymer nanoparticles: downregulating mRNA expression level and sensitizing cancer cells to anticancer drug. Biomacromolecules. 2008; 10(1):41-8. DOI: 10.1021/bm801109g. View

20.

Lee Y, Thompson D . Stimuli-responsive liposomes for drug delivery. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2017; 9(5). PMC: 5557698. DOI: 10.1002/wnan.1450. View